Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis.

Lupus Sci Med · 2026 · PMC12820815 · PMID 41545288

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The NMA indicated a trend toward higher efficacy with telitacicept, although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.